Table 1_Global evidence on the cost-effectiveness of cardiac resynchronization therapy for

A systematic review of 18 studies evaluating the cost-effectiveness of cardiac resynchronization therapy (CRT) for heart failure. The review, authored by Kaltrina Bajraktari and last updated in May 2026, synthesizes evidence on incremental cost-effectiveness ratios (ICERs) from studies published between 2004 and 2025. It compares CRT plus optimal medical therapy to medical therapy alone, as well as CRT-P versus CRT-D devices.

Use Cases

• Benchmarking cost-effectiveness of medical devices based on reported ICERs and QALYs.
• Informing health technology assessment decisions for cardiac resynchronization therapy.
• Analyzing cost variability between CRT-P and CRT-D device types based on the review's findings.

Strengths

• Includes 18 studies meeting defined inclusion criteria, providing a consolidated evidence base.
• Costs were standardized to 2024 euros and assessed against country-specific willingness-to-pay thresholds.
• The review protocol was registered in PROSPERO (CRD420251171292), indicating a structured methodology.

Limitations

• The dataset is a 271.5 KB DOCX file, which is a small document rather than a structured data table.
• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for quantitative analysis.

Provenance

Source

figshare, authored by Kaltrina Bajraktari.

Collection Method

Systematic search of Web of Science, PubMed, and Scopus from January 2004 to July 2025.

Time Range

Studies published from 2004 to 2025.

Freshness

Last updated 2026-05-21 12:55:04; freshness should be verified.

Geography

Global evidence from multiple healthcare settings.